VOTRIENT

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug VOTRIENT contains one active pharmaceutical ingredient (API):

1	Pazopanib UNII 33Y9ANM545 - PAZOPANIB HYDROCHLORIDE
	Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, platelet-derived growth factor (PDGFR) -α and -β, and stem cell factor receptor (c-KIT), with IC50 values of 10, 30, 47, 71, 84 and 74 nM, respectively.
	Read more about Pazopanib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VOTRIENT Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX03	Pazopanib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10041L, 10042M, 10043N, 10047T, 10052C, 10054E, 11252F, 11261Q, 2029T, 2030W, 2201W, 2232L
BR	Câmara de Regulação do Mercado de Medicamentos	526517050089517, 526517050089617, 526517050089717
CA	Health Products and Food Branch	02352303
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	2776-MEE-0517
EE	Ravimiamet	1482027, 1482038, 1482049, 1482050
ES	Centro de información online de medicamentos de la AEMPS	10628001, 10628004
FI	Lääkealan turvallisuus- ja kehittämiskeskus	058261, 085366
FR	Base de données publique des médicaments	62894653, 63803884
GB	Medicines & Healthcare Products Regulatory Agency	174621, 174624
HK	Department of Health Drug Office	60351, 60352, 62096, 62097
IE	Health Products Regulatory Authority	88558, 88559
IL	מִשְׂרַד הַבְּרִיאוּת	6703, 6705
IT	Agenzia del Farmaco	039945011, 039945023, 039945035, 039945047
JP	医薬品医療機器総合機構	4291028F1023
LT	Valstybinė vaistų kontrolės tarnyba	1055472, 1055473, 1055474, 1055475
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	174M2011
NL	Z-Index G-Standaard, PRK	95265, 95273
NZ	Medicines and Medical Devices Safety Authority	13984, 13985
PL	Rejestru Produktów Leczniczych	100222878, 100222884
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64502001, W64502002, W64503001, W64503002
SG	Health Sciences Authority	14022P, 14023P
TN	Direction de la Pharmacie et du Médicament	1243091, 1243092
TR	İlaç ve Tıbbi Cihaz Kurumu	8699504092134, 8699504092141, 8699504092158, 8699504092165
US	FDA, National Drug Code	0078-0670
ZA	Health Products Regulatory Authority	44/26/0348, 44/26/0349